UBS Maintains Buy on Versigent, Raises Price Target to $49

Versigent PLC

Versigent PLC

VGNT

0.00

UBS analyst Joseph Spak maintains Versigent (NYSE: VGNT) with a Buy and raises the price target from $43 to $49.